| Literature DB >> 31527652 |
Roger Luiz Rodrigues1, Gabriela De Lima Menezes2, Marielena Vogel Saivish1, Vivaldo Gomes Da Costa3, Maristela Pereira4, Marcos Lázaro Moreli5, Roosevelt Alves Da Silva6.
Abstract
The Mayaro virus is endemic to South America, and the possible involvement of Aedes spp. mosquitoes in its transmission is a risk factor for outbreaks of greater proportions. The virus causes a potentially disabling illness known as Mayaro fever, which is similar to that caused by the chikungunya virus. The cocirculation of both viruses, with their clinical and structural similarities, and the absence of prophylactic and therapeutic measures highlight the need for studies that seek to understand the Mayaro virus. Using approaches in silico, we identified an antigenic and specific epitope (p_MAYV4) in domain A of the E2 glycoprotein of the Mayaro virus. This epitope was theoretically predicted to be stable and exposed on the surface of the protein, where it showed key properties that enable its interaction with neutralizing antibodies. These characteristics make it an interesting target for the development of immunodiagnostic platforms. Molecular dynamics simulation-based structural analysis showed that the PHE95 residue in the E1 fusion loop region is conserved among Alphavirus family members. PHE95 interacts with the hydrophobic residues of the E2 glycoprotein to form a cage-shaped structure that is critical to assemble and stabilize the E1/E2 heterodimer. These results provide important insights useful for the advancement of diagnostic platforms and the study of therapeutic alternatives.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31527652 PMCID: PMC6746749 DOI: 10.1038/s41598-019-50008-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Predicted B-cell epitopes for E2 glycoproteins of Mayaro and Chikungunya viruses.
| Start | End | Peptide IEDBa | Length | VaxiJen Scoreb | ||
|---|---|---|---|---|---|---|
| p_MAYV1 | 12 | 21 | TRPYVAYCAD | 12 | −0.4159 | MAYV |
|
|
|
|
|
| ||
| p_MAYV3 | 100 | 105 | FILAKC | 6 | −1.0822 | |
|
|
|
|
|
|
| |
|
|
|
|
|
| ||
|
|
|
|
|
|
| |
| p_MAYV7 | 222 | 231 | VDKCQAYVTS | 10 | −0.1773 | |
| p_MAYV8 | 254 | 259 | VHIPFP | 6 | 0.1979 | |
|
|
|
|
|
|
| |
| p_MAYV10 | 284 | 296 | LSLHPIHPTLLSY | 13 | 1.6888 | |
|
|
|
|
|
|
| |
| p_MAYV12 | 355 | 361 | IEYYYGL | 7 | 0.5225 | |
| p_MAYV13 | 365 | 393 | TTIVVVVAVSVVVLLSVAASVYMCVVARN | 29 | 0.5451 | |
| p_CHIKV1 | 14 | 22 | PYLAHCPDC | 9 | −0.1248 | CHIKV |
| p_CHIKV2 | 27 | 35 | SCHSPVALE | 9 | 0.5933 | |
| p_CHIKV3 | 47 | 54 | KIQVSLQI | 8 | 0.9054 | |
| p_CHIKV4 | 82 | 88 | GLFVRTS | 7 | 1.0914 | |
| p_CHIKV5 | 100 | 105 | FILARC | 6 | −1.1297 | |
| p_CHIKV6 | 122 | 128 | SHSCTHP | 7 | 0.2371 | |
| p_CHIKV7 | 222 | 229 | VDQCHAAV | 8 | −0.2062 | |
| p_CHIKV8 | 225 | 269 | VHIPFPLANVTCRVP | 15 | 0.8076 | |
| p_CHIKV9 | 284 | 295 | IMLLYPDHPTLL | 12 | 0.2245 | |
| p_CHIKV10 | 354 | 362 | EIILYYYEL | 9 | 0.3660 | |
| p_CHIKV11 | 367 | 389 | TAVVLSVASFILLSMVGVAVGMC | 23 | 0.7625 |
aPeptides obtained from the online server Immune Epitope Database and Analysis Resource for the E2 glycoprotein from the Mayaro virus.
bPeptides obtained from the online server VaxiJen 2.0 for the E2 glycoprotein from the Mayaro virus.
cThe online predictor VaxiJen 2.0 did not identify antigenicity for this peptide.
dPeptides have a sequence of residues conserved in the E2 glycoprotein of the chikungunya virus.
Figure 1MD simulation of the MAYV E1/E2 glycoprotein heterodimer over 150 ns. (A) RMSD after MD simulations showing an increase in protein instability between ~ 60–75 ns and the subsequent stabilization of the heterodimer after this period. In the image, the E1/E2 dimer is shown before and after the MD simulation. Structural fluctuation is observed mainly in the E2 domain B. (B) Root mean square fluctuation (RMSF) plot showing the flexibility of the model of the E2 glycoprotein domain B (residues 610–675), a transmembrane region of the E1 glycoprotein (residues 400–442) and E2 glycoprotein (residues 800–859) and some β-linker regions. Below, the heatmap of RMSD value per residue as obtained during the 150 ns trajectory for the E1/E2 heterodimer. The scale shows the fluctuation of residues principally in the transmembrane regions of the monomers (darker colors). (C) Results from the cluster analyses of protein trajectories obtained during the simulation. A cut-off point of 0.25 nm was selected to include the major structures during the simulations. The graph shows the stabilization of cluster #1 after ~80 ns. The three main clusters (1, 2 and 3) obtained during the simulation overlap, highlighting fluctuations in the domain B region of the E2 glycoprotein. Note that the clusters oscillate mainly before the stabilization period of the RMSD, and after the stabilization period of the heterodimer (~80 ns), the predominance of cluster 1 is observed. (D) MAYV E1/E2 heterodimer model (cluster #1) in Ribbon, representing the most stable and frequent structure over the simulation. The E1 glycoprotein comprises residues 1–436 and the E2 glycoprotein residues 438–859. In the simulation, position 437 represents the glycan.
Figure 2Analysis of the solvent-accessible surface area (SASA) of the p_MAYV4a peptide. (A) Ribbon structure showing the three-dimensional structure of the peptide in yellow in domain A of the E2 glycoprotein. It is noteworthy that the proposed peptide is composed of a β-sheet structure and a loop region responsible for increasing its antigenicity. (B) Visualization of the exposed peptide surface in the three-dimensional structure of the dimer. The p_MAYV4a peptide is yellow; E1 is red; and E2 is blue. The loop region forms a protrusion on the surface of the molecule into the surrounding environment, and the β-sheet region is buried inside the E2 glycoprotein. (C) Surface exposure of the peptide region (residues 545–557) along the simulation trajectory of 150 ns. The minimum area of exposure was 47.77 nm2, and the maximum was 51.4 nm2. (D) The Region of the peptide composed of hydrophobic residues (β-sheet) as seen in ribbon representation and showing hydrogen interactions (red dotted lines in the antiparallel structures).
Figure 3Region of contact between the E1 glycoprotein fusion loop and the E2 glycoprotein pocket. (A) Ribbon representation showing the formation of the cage-shaped structure by the residues GLN226, TYR228 and ARG178 of the E2 glycoprotein around the PHE95 residue in the E1 fusion loop. (B) Surface representation of residues GLN226, TYR228 and ARG178 of E2 (yellow) interacting with the PHE95 residue in the E1 fusion loop (green). The ribbon structure of the E1 glycoprotein is represented in blue, and the E2 glycoprotein is represented in red. (C) Plot showing the distance between residues ARG178, GLN226 and TYR228 relative to PHE95 in the fused region between the E1 and E2 monomers along the MD simulation trajectory of 150 ns. SASA of the PHE95 residue over the 150 ns simulation is shown in green (the SASA mean was 5.88 nm2). (D) Surface representation of the E1/E2 glycoprotein heterodimer highlighting residues PHE95 and TRP89 (yellow) that form a structure with clamp activity around the E2 glycoprotein (blue).